All stock reports

BIOCON evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • Financial data quality flags require resolution.
  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-01T14:00:34.056947+00:00

Metrics

latest_annual_period
2026-03-31
revenue
169270000000.0
net_income
3856000000.0
operating_cash_flow
12766000000.0
free_cash_flow
-5213000000.0
total_assets
636506000000.0
total_liabilities
270291000000.0
total_equity
340318000000.0
cash
38834000000.0
total_debt
154341000000.0
revenue_growth
0.10911628455545586
earnings_growth
-0.6194611664857397
net_margin
0.02278017368700892
roe
0.011330579046656363
debt_to_equity
0.45351994311203053
cash_conversion
3.3106846473029043
free_cash_flow_margin
-0.030796951615761802
trailing_pe
151.9107
forward_pe
19.802
peg_ratio
Not supplied
price_to_book
2.0627
dividend_yield
0.0012

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Price Dislocation

Research only. Direction: LONG.

Flags large price dislocations for research without asserting unsupported fundamental quality

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Continued price deterioration or adverse fundamental evidence
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-bd039459f1b21933349aecbbdab9fb28b69b01802569ae69d1cbdb10f4ad5c2b
Policy
stock-decisions-v1
Evidence bundle hash
79f2dccf0d8944480157821e847ac7d395205b06e751028cfbffabbf71db1e7e
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 2da0bb362916a3a9aa9539bc003785fc7db0607eb156d9503b5ea92245a43e30
  • daily-price: 067f1bff0855a4f414e7e787f340061223d6062ec2ce12d785ab604864fe797d
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: VERIFIED. The cached closing price on 2026-10-01 was INR 370.70. The trailing 5-session price return was -4.21%. The trailing 20-session price return was -7.56%. The trailing 60-session price return was -6.91%. The trailing 250-session price return was 9.50%.

Risks

Average cached traded value over twenty sessions was INR 1,277,071,235. The closing price was -16.13% below its highest close in the available trailing year. The cached financial metric free cash flow margin is -0.030796951615761802. Financial data check: balance_sheet_equation: difference=25897000000.00. Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Follow Up

Fundamental coverage is FULL_STATEMENTS; retrieved 2026-09-01T14:00:34.056947+00:00 from EODHD. The cached financial metric latest annual period is 2026-03-31. The cached financial metric revenue growth is 0.10911628455545586. The cached financial metric net margin is 0.02278017368700892. The cached financial metric roe is 0.011330579046656363. The cached financial metric debt to equity is 0.45351994311203053.

Cached observations and evidence limits